Gusperimus - CAS 104317-84-2
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Gusperimus is a derivative of the antitumor antibiotic spergualin with immunosuppressant activity. Gusperimus inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells; this agent may suppress growth of certain T-cell leukemia cell lines.
Publictions citing BOC Sciences Products
  • >> More
deoxyspergualin; Deoxyspergualin Hydrochloride; Gusperimus Trihydrochloride; BMS-181173; BMY-42215-1; NKT-01.
Current Developer:
Bristol-Myers Squibb.
1.Gusperimus: immunological mechanism and clinical applications.
Perenyei M1, Jayne DR1, Floßmann O2. Rheumatology (Oxford). 2014 Oct;53(10):1732-41. doi: 10.1093/rheumatology/ket451. Epub 2014 Feb 5.
Gusperimus is an immunosuppressive drug with a unique mode of action. We review its effects on different arms of the immune system and the current evidence for clinical applications, particularly in the treatment of transplant rejection and ANCA-associated vasculitis.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 104317-84-2 Gusperimus

Quick Inquiry

Verification code

Featured Items